Category Archives: Dubious statistics

Aducanumab Approval, Part 2: Dirty Drug Dealings

Yves here. We’re doing a bit of catchup by featuring some significant stories that were still crowded out a bit due to the competing news plus the Fourth of July tuneout. One is on the super dodgy approval of the big ticket, very dubious effectiveness Alzheimer’s drug Aducanumab. And “big ticket” is no understatement; the […]